BOSTON – A technology platform by Akili Interactive Labs detected a statistically significant difference between subjects with and without brain amyloidosis, the primary biomarker for Alzheimer’s risk, according to a study by Akili and Pfizer.
The technology used in the study was Akili’s cognitive assessment tool, which is designed to operate as a fast-paced action video game on a tablet.
“These initial results suggest that our digital biomarkers may have the potential to serve as non-invasive options to screening procedures such as PET imaging scans requiring the administration of radioactive ligands or lumbar punctures,” said Eddie Martucci, president and CEO of Akili, in a statement.
Akili’s technology was able to differentiate between older health subjects positive for amyloid deposits in their brains versus an age-matched comparison group of amyloid-negative subjects.
The double-blind study was conducted as a parallel protocol where participants were accepted into the study only if they were judged healthy by screening criteria. Participants were then given a quantitative PET scan to determine brain amyloid presence.
The collaboration between Akili and Pfizer was established in 2014 to assess the potential correlation between Akili’s proprietary digital biomarkers and one or more of the accepted neurological markers for asymptomatic Alzheimer’s Disease.
“We are encouraged by the results of this trial, and we look forward to exploring ways that we might be able to implement innovative new technologies like the Akili platform into the clinical trial process,” said Ole Isaacson, senior vice president and chief scientific officer, Neuroscience, at Pfizer, in a statement.